Full Breakdown
Trump Administration Moves to Reclassify Marijuana
4/23/2026, 11:33:49 PM
Federal Reclassification of Marijuana
The Trump administration is poised to take significant steps toward loosening federal restrictions on marijuana, potentially reclassifying the drug from a Schedule I to a Schedule III substance under U.S. law. This change, as reported by The Washington Post, could be announced imminently and would initiate formal proceedings by the Drug Enforcement Administration (DEA) to consider the rescheduling. Currently classified as Schedule I, marijuana is deemed to have no accepted medical use and a high potential for abuse, alongside substances like heroin and cocaine. A shift to Schedule III would recognize its medical applications, thereby easing regulatory barriers for research and reducing tax burdens on cannabis businesses.
Implications of Rescheduling
Rescheduling marijuana would not legalize the drug but could lessen the severity of federal enforcement and open avenues for medical research. The current effective tax rate for cannabis companies stands at approximately 60% of gross revenue, a burden that could be alleviated through reclassification. The move is seen as a historic shift in federal drug policy, with potential benefits for medical research institutions seeking to study cannabinoids like THC and CBD. Adam Smith, executive director of the Marijuana Policy Project, emphasized that this change would acknowledge the long-recognized medical uses of cannabis.
Background and Context
The push for reclassification follows a directive from President Trump, who signed an executive order in December 2025, instructing federal agencies to expedite reviews of certain psychedelic drugs and marijuana. This initiative builds on efforts from the Biden administration, which had begun federal reviews to assess marijuana's medical uses but faced bureaucratic delays. While Trump does not have the direct authority to reschedule marijuana, he can guide federal agencies to undertake the process, which the DEA is now following.
Criticism and Opposition
Despite the potential benefits of reclassification, critics argue that this move does not address the broader issues surrounding cannabis legalization and the impact on individuals incarcerated for marijuana-related offenses. Smith noted that while rescheduling is a positive step, it does not resolve all issues, particularly the need for decriminalization. Over 200,000 Americans were arrested for cannabis-related offenses last year, highlighting ongoing challenges in the legal landscape.
Official Statements & Responses
In a recent statement, Trump expressed frustration with the pace of the rescheduling process, saying, “Will you get the rescheduling done, please? Joe, they’re slow-walking me on rescheduling.” This sentiment reflects the urgency the administration feels regarding the reclassification.
What's Next
The timeline for any changes remains uncertain, as the process will require regulatory review and administrative hearings, which may face legal challenges before final approval. The outcome of this initiative could significantly reshape the federal approach to marijuana and its implications for medical research and the cannabis industry.
